Skip to main content
SpringerLink
Log in

Metabolic Modulation in Heart Failure: The Coming of Age

  • Editorial
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics-2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85–151.

    Article  PubMed  Google Scholar 

  2. Swedberg K, Cleland J, Dargie H, for the The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115–40.

    Article  PubMed  CAS  Google Scholar 

  3. Bing, RJ. The metabolism of the heart. Harvey Lect 1954;50:27–70.

    PubMed  Google Scholar 

  4. Ferrari R, Cargnoni A, Ceconi C. Anti-ischaemic effect of ivabradine. Pharmacol Res 2006;53:435–9.

    Article  PubMed  CAS  Google Scholar 

  5. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004;95:135–45.

    Article  PubMed  CAS  Google Scholar 

  6. De Brouwer KF, Degens H, Aartsen WM, et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J Mol Cell Cardiol 2006;40:838–45.

    Article  PubMed  CAS  Google Scholar 

  7. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 2006;114:1151–8.

    Article  PubMed  CAS  Google Scholar 

  8. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093–129.

    Article  PubMed  CAS  Google Scholar 

  9. Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005;54:3496–502.

    Article  PubMed  CAS  Google Scholar 

  10. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 1971;50:1386–9.

    Article  PubMed  CAS  Google Scholar 

  11. Rupp H, Rupp TP, Maisch B. Fatty acid oxidation inhibition with PPAR[alpha] activation (FOXIB/PPAR[alpha]) for normalizing gene expression in heart failure? Cardiovasc Res 2005;66:423–6.

    Article  PubMed  CAS  Google Scholar 

  12. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000;99:27–35.

    Article  PubMed  CAS  Google Scholar 

  13. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003;93:e33–7.

    Article  PubMed  CAS  Google Scholar 

  14. Kennedy JA, Horowitz JD. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc Drugs Ther 1998;12:359–63.

    Article  PubMed  CAS  Google Scholar 

  15. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634–41.

    Article  PubMed  CAS  Google Scholar 

  16. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280–8.

    Article  PubMed  CAS  Google Scholar 

  17. Fragasso G, Palloshi A, Puccetti P. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992–8.

    Article  PubMed  CAS  Google Scholar 

  18. Tang WH. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice. J Am Coll Cardiol 2006;48:999–1000.

    Article  PubMed  Google Scholar 

  19. Cohn JN. Efficacy and safety in clinical trials in cardiovascular disease. J Am Coll Cardiol 2006;48:430–3.

    Article  PubMed  Google Scholar 

  20. Granger CB, McMurray JJ. Using measures of disease progression to determine therapeutic effect: a sirens’ song. J Am Coll Cardiol 2006;48:434–7.

    Article  PubMed  Google Scholar 

  21. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006; 114(20):2130–7.

    Article  PubMed  CAS  Google Scholar 

  22. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001;1:193–204.

    Article  PubMed  CAS  Google Scholar 

  23. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

    Houman Ashrafian & Michael P. Frenneaux

  2. Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK

    Houman Ashrafian

Authors
  1. Houman Ashrafian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Frenneaux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Houman Ashrafian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ashrafian, H., Frenneaux, M.P. Metabolic Modulation in Heart Failure: The Coming of Age. Cardiovasc Drugs Ther 21, 5–7 (2007). https://doi.org/10.1007/s10557-007-6000-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-007-6000-z

Key words

Search

Navigation